Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting

被引:99
作者
Barch, Deanna M. [1 ]
Carter, Cameron S. [2 ]
Arnsten, Amy [3 ]
Buchanan, Robert W. [4 ]
Cohen, Jonathan D. [5 ]
Geyer, Mark [6 ]
Green, Michael F. [7 ,8 ]
Krystal, John H. [3 ]
Nuechterlein, Keith [9 ]
Robbins, Trevor [10 ]
Silverstein, Steven [11 ]
Smith, Edward E. [12 ]
Strauss, Milton [13 ]
Wykes, Til [14 ]
Heinssen, Robert [15 ]
机构
[1] Washington Univ, St Louis, MO 63130 USA
[2] Univ Calif Davis, Davis, CA 95616 USA
[3] Yale Univ, New Haven, CT USA
[4] Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA
[5] Princeton Univ, Princeton, NJ 08544 USA
[6] Univ Calif San Diego, San Diego, CA 92103 USA
[7] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA
[8] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] Univ Cambridge, Cambridge, England
[11] Univ Med & Dent New Jersey, Rutgers, NJ USA
[12] Columbia Univ, New York, NY USA
[13] Univ New Mexico, Albuquerque, NM USA
[14] Kings Coll London, Inst Psychiat, London, England
[15] NIMH, Bethesda, MD 20892 USA
关键词
IMPROVE COGNITION; SCHIZOPHRENIA; TARGETS; ENHANCEMENT; RECEPTORS; DEFICITS; SIZE;
D O I
10.1093/schbul/sbn163
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This overview describes the goals and objectives of the third conference conducted as part of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative. This third conference was focused on selecting specific paradigms from cognitive neuroscience that measured the constructs identified in the first CNTRICS meeting, with the goal of facilitating the translation of these paradigms into use in clinical trials contexts. To identify such paradigms, we had an open nomination process in which the field was asked to nominate potentially relevant paradigms and to provide information on several domains relevant to selecting the most promising tasks for each construct (eg, construct validity, neural bases, psychometrics, availability of animal models). Our goal was to identify 1-2 promising tasks for each of the 11 constructs identified at the first CNTRICS meeting. In this overview article, we describe the on-line survey used to generate nominations for promising tasks, the criteria that were used to select the tasks, the rationale behind the criteria, and the ways in which breakout groups worked together to identify the most promising tasks from among those nominated. This article serves as an introduction to the set of 6 articles included in this special issue that provide information about the specific tasks discussed and selected for the constructs from each of 6 broad domains (working memory, executive control, attention, long-term memory, perception, and social cognition).
引用
收藏
页码:109 / 114
页数:6
相关论文
共 17 条
[1]   Adrenergic targets for the treatment of cognitive deficits in schizophrenia [J].
Arnsten, AFT .
PSYCHOPHARMACOLOGY, 2004, 174 (01) :25-31
[2]   Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: A report of the second consensus building conference of the CNTRICS initiative [J].
Barch, Deanna M. ;
Carter, Cameron S. .
SCHIZOPHRENIA BULLETIN, 2008, 34 (04) :613-618
[3]   Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia initiative [J].
Carter, Cameron S. ;
Barch, Deanna M. ;
Buchanan, Robert W. ;
Bullmore, Edward T. ;
Krystal, John H. ;
Cohen, Jonathan ;
Geyer, Mark ;
Green, Michael ;
Nuechterlein, Keith H. ;
Robbins, Trevor ;
Silverstein, Steven ;
Smith, Edward E. ;
Strauss, Milton ;
Wykes, Til ;
Heinssen, Robert .
BIOLOGICAL PSYCHIATRY, 2008, 64 (01) :4-10
[4]   Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: The CNTRICS initiative [J].
Carter, Cameron S. ;
Barch, Deanna M. .
SCHIZOPHRENIA BULLETIN, 2007, 33 (05) :1131-1137
[5]   Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists [J].
Friedman, JI .
PSYCHOPHARMACOLOGY, 2004, 174 (01) :45-53
[6]   Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria [J].
Green, MF ;
Nuechterlein, KH ;
Gold, JM ;
Barch, DM ;
Cohen, J ;
Essock, S ;
Fenton, WS ;
Frese, F ;
Goldberg, TE ;
Heaton, RK ;
Keefe, RSE ;
Kern, RS ;
Kraemer, H ;
Stover, E ;
Weinberger, DR ;
Zalcman, S ;
Marder, SR .
BIOLOGICAL PSYCHIATRY, 2004, 56 (05) :301-307
[7]   Implementation considerations for multisite clinical trials with cognitive neuroscience tasks [J].
Keefe, Richard S. E. ;
Harvey, Philip D. .
SCHIZOPHRENIA BULLETIN, 2008, 34 (04) :656-663
[8]   Implications of clinical trial design on sample size requirements [J].
Leon, Andrew C. .
SCHIZOPHRENIA BULLETIN, 2008, 34 (04) :664-669
[9]   Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction [J].
Lewis, DA ;
Volk, DW ;
Hashimoto, T .
PSYCHOPHARMACOLOGY, 2004, 174 (01) :143-150
[10]   The translation of cognitive paradigms for patient research [J].
Luck, Steven J. ;
Gold, James M. .
SCHIZOPHRENIA BULLETIN, 2008, 34 (04) :629-644